title: GSM7508909: HF/AF-4; Homo sapiens; RNA-Seq
library_construction_protocol: Peripheral blood was obtained from 4 patients who had heart failure with atrial fibrillation (HF /AF group) and 4 matched healthy subjects (control group) who excluded HF and AF by ethylenediaminetetraacetic acid disodium salt (EDTA) tubes. The diagnosis of HF and AF were in accordance with the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and Atrial fibrillation: Current understanding and Treatment Recommendations (2021) respectively. According to the Declaration of Helsinki, ethical approval was accepted by the Ethics Committee of First Hospital of Shanxi Medical University and all participants had written informed consent. The patients of the HF/AF group were excluded from hypertension, coronary heart disease, OSA, diabetes, rheumatic disease, valvular heart disease, infectious disease, tumor as well as the dysfunction of the liver and renal. The matched participants of control had sinus rhythm and were in good condition. The HF/AF group was higher than the control group in NT-proBNP. The HF/AF group was significantly lower than the control group in the aspect of ejection fraction (EF). There was no statistical difference in the aspects of age, gender, smoking status and obesity. A total amount of 3 μg RNA per sample was used as input material for the RNA sample preparations. Firstly,ribosomal RNA was removed by Epicentre Ribo-zero™ rRNA Removal Kit (Epicentre, USA), and rRNA free residue was cleaned up by ethanol precipitation. Subsequently, sequencing libraries were generated using the rRNA-depleted RNA by NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, USA) following manufacturer's recommendations.